Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced that it has completed the redemption of all US$130,000,000 (Cdn$175,669,000) principal amount of its outstanding 9.75% senior secured notes due 2024 (CUSIP: 89788CAB0 ISIN: CA89788CAB06) (the "Notes"). Cash used for the redemption was approximately US$136 million ( Cdn$184 million ), which included the aggregate principal amount of the Notes being redeemed, plus accrued and unpaid interest to, but excluding, the redemption date of December 1, 2023 . The Notes will cease to trade on the Canadian Securities Exchange under the symbol "TRUL.DB.U" as of the close of trading on December 1, 2023 and will be delisted as of December 1, 2023 . Additional information regarding the redemption of the Notes is available from Odyssey Trust Co.
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports

Melodiol Subsidiary Mernova Medicinal Inc. Scales Up As Q3 Sales Momentum Accelerates
Melodiol Global Health Limited (ASX:ME1, FRA:1X8) (‘Melodiol’ or ‘the Company’) ) is pleased to provide this trading update for its 100% owned Canadian subsidiary, Mernova Medical Inc (‘Mernova’) following a strong start to the September quarter across its key target markets in Canada.
Highlights:
- Mernova Medicinal Inc. (“Mernova”) has recorded strong sales revenue and confirmed purchase orders (POs) in the September quarter to-date (approximately half a quarter) of $1.3 m1 (CA$1.135m);
- Mernova on track to again achieve significant quarter on quarter growth, with Q3 revenue to date of $1.3m only half way through the quarter, compared to Q2 full quarter revenue of $1.5m;
- In addition to its strong focus on sales growth, Mernova continues to advance its compliance pathway for GMP (Good Manufacturing Practice) certification
With increasing traction across multiple Canadian products for its leading range of cannabis products, Mernova remains on track to deliver further growth with monthly sales accelerating further following strong July and August to date figures.
Aggregate sales and confirmed POs across July and August to-date now total $1.3m (CA$1.135m) for approximately half of the quarter, which compares favourably to Q2 full quarter record revenues of $1.5m.
Along with strong sales across its product range in core target markets, the Company recently made its formal market entry to Alberta province after meeting key regulatory compliance standards in the region.
Alberta is the second largest provincial cannabis market nationally in Canada, and maintains strict compliance requirements which gives Mernova a competitive advantage following its successful submission process. Alberta marks the eighth province where Mernova has been approved to sell its leading range of licensed cannabis products, and the Company expects to book first sales in Alberta prior to the end of August for six stock-keeping units (SKUs) that have now been approved for sale.
The group’s sales momentum across major markets in Canada will also be complemented by the launch of new rebranded product logos and packages and a revamped website, which have been approved for production and scheduled for soft launch later this week.
As revenue accelerates, Mernova remains committed to making cannabis products that adhere to the highest Good Manufacturing Practices (GMP) standards. The Company is now in the process of finalising its Vendor Qualification SOP documentation, and addressing final gaps in consultation with regulators in order to complete its Quality Risk Assessment framework.
During the quarter, Mernova has also advanced its Validation Master Plan documentation to formally align its development pathway with designated GMP steps and is working on a Site Master Plan to meet GMP requirements.
Chief Executive Officer Mr William Lay said: “This trading update confirms the strong traction that Mernova has now established throughout the national cannabis market in Canada. We are particularly pleased with the Company’s revenue run-rate in the September quarter to-date, which leaves it on track to underpin further growth for the group. Equally however, it’s pleasing to note the group’s progress with respect to its national distribution network and ongoing compliance initiatives to ensure it can produce cannabis products at scale to the highest standards of quality and compliance. Mernova’s successful entry into Alberta opens up a signficaint new addressable market for the Company, providing further upside at a point where revenue growth in its core target markets is already accelerating. With further operational updates pending in the second half of 2023, in line with the Company’s stated growth strategy, we are excited by the opportunity for Mernova to consodliate its position as a leading cannabis business in the North American market.”
About Melodiol
Melodiol Global Health Limited (ASX:ME1) brings the best of cannabis and other plant-based products to better the lives of people and animals. Melodiol strives for the highest quality in its products. It develops cannabis, hemp-derived and other plant based therapeutic, nutraceutical, and lifestyle products with wide consumer reach.
Click here for the full ASX Release
This article includes content from Melodial Global Health, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
Melodiol Global Health Investor Kit
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
Trulieve Announces Completion of Redemption of All US$130 Million 9.75% Senior Secured Notes due 2024
News Provided by Canada Newswire via QuoteMedia
Cannabis Stocks: 10 Biggest Companies
The cannabis industry faced similar obstacles in 2023 as it did in 2022, with a lack of reform both in the United States and Canada proving to be a significant roadblock to growth in the market.
With the year almost behind us, here the Investing News Network recounts the performance of some of the largest cannabis stocks out there.
This list was put together based on the top-weighted pure cannabis stocks included in the AdvisorShares Pure US Cannabis ETF (ARCA:MSOS) and the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ) as of November 30, 2023. Share information for companies is accurate as of November 30.
US operators
Cannabis remains illegal at the federal level in the US, but state market openings have allowed some US-based operators to thrive. Typically these firms set up vertically integrated businesses with a focus on branded products, retail networks and licenses.
While these companies have adapted to regulatory challenges, they have much to gain from country-level reform in the US, and are eager to see more welcoming federal laws that will allow their businesses to develop further.
US-focused cannabis fund
The AdvisorShares Pure US Cannabis ETF (NYSEARCA:MSOS) provides investors with exposure to companies exclusively operating within the US cannabis industry.
By investing in companies that are working in states with clear guidelines, MSOS gives investors a way to be more selective about the types of cannabis companies they're investing in, rather than just investing in the industry as a whole.
MSOS has decreased in value by 0.73 percent in 2023, resulting in a price point of US$6.82 as of November 30.
1. Green Thumb Industries (CSE:GTII,OTCQX:GTBIF)
ETF weight: 25.94 percent; market cap: US$2.48 billion; current share price: US$10.48
Green Thumb Industries makes up 25.94 percent of the MSOS ETF. It is a multi-state operator (MSO) with headquarters in Chicago, Illinois. Green Thumb Industries produces and sells cannabis products for recreational and medical use out of 87 stores across 15 states.
The third quarter of 2023 was a significant period for the company, which reported revenue of US$275 million and GAAP income of US$11 million. These figures represent a 9 percent increase in revenue over the previous quarter. The company has attributed such explosive growth to the start of adult-use sales at Green Thumb’s four cannabis shops in Maryland following legalization on July 1.
2. Curaleaf Holdings (CSE:CURA,OTCQX:CURLF)
ETF weight: 19.33 percent; market cap: US$2.66 billion; current share price: US$3.77
Curaleaf Holdings has a significant presence in the US cannabis market, with 146 dispensaries and 21 cultivation centers in 18 states, making them a major player in the industry. The company is also continuing its expansion into the European cannabis market with the anticipated increase in demand for medical cannabis products, especially in Germany and the UK, where the company already has a significant presence. The company applied to be uplisted to the TSX on October 10 and is awaiting approval.
Curaleaf is one of the many companies in the US that are optimizing their operations to cope with the challenges of the industry. Q3 saw Curaleaf complete the final steps of the company’s asset optimization plan, which included reducing inventory and adding new product offerings. The company’s Q3 2023 results reported revenue of US$333 million, representing a year-over-year increase of two percent, and an adjusted EBITDA margin of 23 percent. In a statement released alongside the results, Executive Chairman Boris Jordan said he was “pleased that (Curaleaf’s) changes are showing results.”
3. Verano Holdings (NEO:VRNO,OTCQX:VRNOF)
ETF weight: 14.64 percent; market cap US$1.02 billion; current share price: US$5.50
Verano Holdings is a vertically integrated, premiere cannabis company. It delivers high-quality products out of its 136 chic Zen Leaf and MÜV retail locations, spread across 13 states. The company reported a revenue of US$240 million during its Q3 results conference call on November 8, representing year-over-year growth of five percent.
Unlike other US operators listed on a Canadian exchange, Verano recently moved its listing to the Cboe from the CSE, opting not to apply for a TSX listing. The move is expected to increase the company's visibility and accessibility to investors, while at the same time leaving it in a better position to transition to a US exchange if cannabis is legalized there, according to the company’s CEO George Archos.
4. Trulieve Cannabis (CSE:TRUL,OTCQX:TCNNF)
ETF weight: 11.9 percent; market cap: US$1.02 billion; current share price: US$5.50
Truelieve Cannabis is a vertically integrated medical marijuana company with a dominant market share in its home state of Florida.
Trulieve Cannabis recently announced that it would be redeeming its 9.75 percent senior secured notes, worth US$130 million, on December 1, six months ahead of the original due date in June 2024. This comes on the heels of a strong third quarter for the company, with retail sales accounting for 96 percent of its total revenue of US$275 million.
5. TerrAscend (CSE:TER,OTCQX:TRSSF)
ETF weight: 6.89 percent; market cap: US$558.69 million; current share price: US$1.67
TerrAscend is a vertically integrated MSO with operations in the US as well as Canada. Its diversified ownership structure is a good representation of the growing interest in the cannabis industry from various sources.
TerrAscend has 37 dispensaries in five states, including six medical dispensaries in Pennsylvania and four in Maryland, where adult-use recreational cannabis became legal this year. TerrAscend also has a strong presence in New Jersey, with retail stores and a state-of-the-art cultivation and production facility. The Garden State is the company’s most profitable market, and the company’s Q3 2023 report revealed that TerrAscend had climbed to second place in market share in the state at 18.6 percent — less than 1 percent from the top spot.
TerrAscend’s Q3 net revenue was up 34.7 percent year-over-year, jumping from US$66.2 million to a record US$89.2 million.
Canadian growers
In 2018, Canada became the first G7 nation to legalize adult-use cannabis and create its own streamlined program regulated by both federal and provincial powers. Since then, companies working in the country have faced ups and downs in dealing with tight marketing rules, high tax rates and ongoing competition with the unregulated market.
Canada-based cannabis fund
The Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ) was the first cannabis ETF available in Canada, and it holds a variety of companies involved in cannabis in some way along with several non-flower companies. For this list, instead of solely considering ETF weight, we will only be including companies that have notable involvement with the cannabis industry.
While the HMMJ does not invest in US-based multi-state operators, it does have exposure to the US market through Canadian companies that have interests in the US cannabis industry.
Overall, HMMJ is designed to give investors broad exposure to the cannabis industry, with a particular focus on North American companies.
This ETF hasn’t had the best year, with a year-to-date loss of 27.16 percent as of November 30 and a price point of US$8.61. ETF performance data was gathered on November 28.
1. Innovative Industrial Properties (NYSE:IIPR)
ETF weight:15.72 percent; market cap: US$2.24 billion; current share price: US$25.82
Innovative Industrial Properties (NYSE:IIPR) is a real estate investment trust that provides specialized real estate opportunities for cannabis companies in 19 states. Its properties mostly consist of processing plants, greenhouses and warehouses, with retail spaces making up a small percentage of its portfolio.
IIP has provided long-term absolute net lease agreements to some of the cannabis industry’s biggest names like Green Thumb Industries, Tilt Holdings (NEO:TILT,OTCQB:TLLTF), Ascend Wellness (CSE:AAWH.U,OTCQX:AAWH) and Curaleaf. The company’s attractive sale-leaseback program has helped cannabis companies access a source of capital, a much-needed workaround in the US where there are fewer traditional financing options.
2. Cronos Group (NASDAQ:CRON,TSX:CRON)
ETF weight: 14.73 percent; market cap: US$744.1 million; current share price: US$1.95
Cronos Group is the Canada-based company behind the Spinach, Peace Naturals and Lord Jones cannabis brands. The company recently re-entered the German medical cannabis market through its partnership with a German medical cannabis company called Cansativa Group and is positioned to take advantage of potential adult-use legalization in the country. Cronos also serves the Israeli market through its subsidiary Cronos Israel.
The company’s Q3 results revealed a 22 percent year-over-year net revenue increase, marking one of the “best quarters in Cronos history,” according to Mike Gorenstein, the chairman, president and CEO of the company. Gorenstein also mentioned in the press release that his company had recently agreed to start sending cannabis products to Vitura Health for sale in Australia, further expanding its global reach.
3. Tilray Brands (NASDAQ:TLRY,TSX:TLRY)
ETF weight: 11.22 percent; market cap: US$1.29 billion; share price: US$1.77
Tilray Brands has a presence in over 20 countries worldwide with a wide range of cannabis products including edibles, flower and oils. The company solidified its position as one of the largest players in the global cannabis market after it merged with medical cannabis brand Aphria in 2020. This past June, Tilray announced it had completed an accretive acquisition of HEXO, a cannabis company out of Gatineau, Québec — a move that contributed to a 6 percent year-over-year increase in total revenue on a constant-currency basis.
The bulk of Tilray’s sales lies in the Canadian and international medical cannabis export markets. The company has a relatively small presence in the US and is limited to selling products infused only with CBD.
4. SNDL (NASDAQ:SNDL)
ETF weight: 5.46 percent; market cap: US$366.97 million; current share price: US$1.41
SNDL, formerly known as Sundial Growers, is the largest private-sector liquor and cannabis retailer on the Canadian market. The company has made the headlines quite frequently throughout 2023, notably in October when it chose to close its Olds, Alberta, cannabis facility. Its stock price has fallen more than 40 percent in 2023, but the steps the company has taken to reduce its debt and the introduction of new products to the SNDL lineup have resulted in a positive free cash flow of US$16.5 million in Q3, a 147.5 percent increase from Q3 2022.
Net revenue for cannabis retail and operations has also increased year-over-year. Q3 results reported earnings of US$75.5 million from cannabis retail, an increase of 14.1 percent compared to 2022 and net revenue of US$21 million for cannabis operations, a 77.4 percent increase.
5. Canopy Growth (NASDAQ:CGC,TSX:WEED)
ETF weight: 3.88 percent; market cap: US$447.96 million; current share price: US$0.54
Canopy Growth is a company that’s grown alongside Canada’s cannabis industry. Founded in 2013, it has become one of the largest producers of cannabis in the world, fostering brand deals with celebrities like Martha Stewart and Snoop Dogg.
The company released positive fiscal Q2 2024 results on November 9, indicating that the company was on track for another profitable year, despite the setbacks faced by many in the cannabis industry.
“Our financial results demonstrated marked improvement this quarter, including significant gross margin gains and reduced cash burn. This enhanced performance, together with a series of completed balance sheet strengthening actions, has solidified our foundation and set the stage for profitable growth ahead,” Chief Financial Officer Judy Hong said in a statement released with the financial report.
FAQs for investing in cannabis
Are cannabis stocks worth investing in?
Each investor will have to think and act for themselves to manage their own risk exposure, but it’s no secret that cannabis stocks have taken a beating for some time now. While financial experts point to the long-term upside of US operators as more state markets expand, the stock market has not been kind to these names lately.
Are cannabis stocks considered a high- or low-risk investment?
Cannabis investments are extremely young in the grand scheme of the investment universe. There is an exciting and refreshing element to these stocks, but the market has always been characterized by volatility and unpredictability.
While wild, spontaneous swings in the open market have become less common, cannabis stocks are often moved — both positively and negatively — by big pieces of market news or legalization updates.
Why do people buy cannabis stocks?
Investors may choose to get exposure to the cannabis market as a way to participate in the development of a new drug market with consumer packaged goods capabilities. Some participants are bullish on the industry's long-term outlook and expect more welcoming laws in the US and across the world to provide upward momentum.
Don’t forget to follow us @INN_Cannabis for real-time updates!
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
Cronos Group Inc. enters into agreement for the sale-leaseback of its Stayner, Ontario facility
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") today announced that its wholly owned subsidiary entered into an agreement (the "Sale Agreement") with Future Farmco Canada Inc. (the "Buyer"), a vertical farming company, for the sale and leaseback of its property located at 4491 Concession 12 Sunnidale Road, Stayner, Ontario, Canada, L0M 1S0 (the "Peace Naturals Campus"). Pursuant to the terms of the Sale Agreement, the Buyer has agreed to acquire the Peace Naturals Campus for C$23 million cash, subject to the terms and conditions set forth therein. The parties also plan to enter into a lease agreement upon closing for portions of the Peace Naturals Campus, ensuring continued operations.
"The sale-leaseback of the Peace Naturals Campus supports Cronos' goal to reduce costs across the Company," said Mike Gorenstein, Chairman, President and CEO, Cronos. "More specifically, this sale will aid in improving the gross margin profile of our business, while lowering costs and increasing our agility. This sale only strengthens our industry-leading balance sheet and allows us to continue to pursue organic growth and future transactions that bolster Cronos' existing value. We do not expect any interruption to our current operations and plan to carry out existing growth plans within our leased space at the facility."
Closing of the transaction is subject to certain conditions outlined in Cronos' Form 8-K . Within 180 days of the Sale Agreement date, the Buyer must confirm in writing that it is satisfied with various aspects of the property and has secured financing for the transaction. Cronos must receive approval from Health Canada for site perimeter changes by the later of: (i) 180 calendar days after the date of the Sale Agreement; or (ii) 75 calendar days after the satisfaction or waiver of the Buyer's condition described above. Additionally, both parties must agree on the terms of a lease within 75 days of the Sale Agreement date. The transaction is expected to close 30 calendar days after all conditions are satisfied or waived.
At closing, the parties expect to enter into a lease agreement for portions of the Peace Naturals Campus, which will include a five-year term and one five-year renewal option that may be exercised by Cronos. Cronos will also have an option to lease certain additional space during the term of the lease. Cronos can choose to terminate the lease without penalty anytime after the second year by giving written notice at least 12 months prior to termination. The leased premises will be identified and agreed between both parties prior to closing.
About Cronos
Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos' diverse international brand portfolio includes Spinach®, PEACE NATURALS® and Lord Jones®. For more information about Cronos and its brands, please visit: thecronosgroup.com.
Forward-looking Statements
This press release may contain information that may constitute "forward-looking information" or "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, "Forward-looking Statements"). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include: the completion of the sale-leaseback of the Peace Naturals Campus and timing thereof; the Company's receipt of required licenses or approvals for license amendments; the parties' ability to agree on the portion of the Peace Naturals Campus to be leased by the Company and the terms of the lease; the duration in which the Company would lease a portion of the Peace Naturals Campus; the effect of the sale-leaseback transaction on the Company's costs and gross margin profile; the impact of the transaction on the Company's balance sheet and ability to pursue organic growth and future transactions that bolster existing value; and statements about Cronos' intention to build an international iconic brand portfolio and develop disruptive intellectual property. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, financial results, results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and quarterly reports on Form 10-Q for the quarters ended March 31, 2023, June 30, 2023, and September 30, 2023, each of which has been filed on SEDAR and EDGAR and can be accessed at www.sedar.com and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.
Investor Relations Contact
Shayne Laidlaw
investor.relations@thecronosgroup.com
Media Relations Contact
Emily Whalen
media.relations@thecronosgroup.com
News Provided by GlobeNewswire via QuoteMedia
Cannabis Weekly Round-Up: New York Aims to Ease Banking Barriers, Wisconsin Issues Pardons
Cannabis businesses in New York are set to receive easier access to banking services.
Meanwhile, Wisconsin's governor was in a giving mood this week — ahead of the Thanksgiving holiday, he granted pardons to dozens of people with with cannabis-related convictions.
Read on to learn what else happened in the cannabis space this week.
New York governor breaks down cannabis banking barriers
On Thursday (November 23), New York Governor Kathy Hochul (D), with the support of Senator Jeremy Cooney (D) and Assembly Member Crystal Peoples-Stokes (D), signed legislation that will help cannabis entrepreneurs gain easier access to financial institutions. The move comes barely a week after Hochul signed into law a piece of legislation that will provide tax relief to struggling cannabis businesses that are unable to file federal tax deductions.
Senate Bill S1047A allows New York's Office of Cannabis Management to, with consent, provide banks with information on cannabis business licensees and applicants. The idea is to alleviate the obstacles faced by banks that want to do business with cannabis clients, but face the time-consuming and costly burden of complying with federal laws.
While important for New York-based cannabis operators, the new law will have no effect on federal banking reform. In September, the SAFER Banking Act, which would allow cannabis companies across the country to access services from financial institutions, made it to the floor of the Senate, but stalled there. Senate Majority Leader Chuck Schumer is now facing an uphill battle to persuade members of the GOP to support the bill; however, in an interview with Yahoo News last weekend, he said he plans to move forward with the bill “as soon as we have those 10 or 11 Republican votes."
Wisconsin governor grants cannabis pardons
Wisconsin Governor Tony Evers (D) granted 82 pardons on Wednesday (November 22). This act of clemency brought his overall tally to 1,111 pardons. According to a press release on his website, approximately one-third of the pardons issued this week were to individuals who were convicted of cannabis possession, cultivation or sale.
“It continues to be a privilege to hear about individuals’ lives, work, and what they have done to overcome their past mistakes and build positive, rewarding lives for themselves and their families,” said Evers.
Teenagers not more likely to use cannabis post-legalization
A research paper conducted by a doctoral candidate and published in a special issue of Clinical Therapeutics suggests that high school students today are at no greater risk of smoking cannabis than they were before legalization.
Faith English, a PhD student at the School of Public Health Sciences at the University of Massachusetts Amherst, is the paper's lead author. She found that high schoolers are more likely to use cannabis if they perceive parents or friends using it, but that they were just as likely to use cannabis under similar circumstances prior to legalization in 2016.
English and senior author Jennifer Whitehill acknowledge that more research is needed to determine whether or not the legalization of cannabis does indeed influence use in adolescents and teenagers, but note that their research suggests influence by peers is a more likely cause of cannabis consumption in adolescents than legalization.
Importantly, the survey reveals a 6 percent increase in the proportion of youth who perceive their parents as cannabis users. The researchers also found a decrease in the percentage of youth who perceive that their best friend uses cannabis — it declined from 69 percent in 2016 to 64 percent in 2018.
Sarasota begins repeal of cannabis civil citation program
On Monday (November 20), the City Commission of Sarasota, Florida, began the process of repealing its cannabis civil citation program in line with police recommendations. The decision comes after a presentation revealed that almost 90 percent of the population does not comply by paying their fines.
In 2019, the City Commission passed an ordinance to decriminalize cannabis, mandating that instead of facing arrest, individuals caught with less than 20 grams of cannabis had the option to pay a US$100 fine or complete 100 hours of community service. The option was open to those over the age of 18 as long as they were not caught smoking the drug.
Sarasota Police Commissioner Debbie Trice told city news publication MySun Coast News that since the inception of the program in 2020, less than 12 percent of violators have complied with issued fines.
“Right now we have a law that is not working,” she said. In light of the low participation rate, the City Commission voted 4 to 1 in favor of drafting an ordinance to repeal the cannabis civil citation program.
Hawaii throws up legalization roadblock
Last week, Hawaii Attorney General Anne Lopez submitted a 294 page proposal for establishing a retail market for adult-use recreational cannabis in the state. The news came as a surprise to many, as Lopez has been opposed to legalizing recreational use for adults; however, the report indicates that her attitude toward legalization is evolving.
Hawaii News Now was the first to report the story, quoting Lopez's forward-thinking, but strict, stance on the issue: “The most important thing we can do is we can bring the people who have been growing and selling cannabis illegally into the legal market. If the dealers don’t go straight, they face a specialized 14-member law enforcement unit. It’s going to be a concerted investigative process to ensure that the law is followed."
The proposal has been well received by lawmakers, but many members of the law enforcement community are concerned that legalization will prove to be too great a risk. Leading a coalition against the proposal is Honolulu City Prosecutor Steve Alm. In an interview with Hawaii News Now, Alm said that there is “no impetus to changing the system," adding that he predicts opposition from health and education experts. He said that in his view, statistics on traffic deaths and emergency room visits in states where cannabis is legal are reason enough to oppose reform.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
Eminent Healthcare Leader Appointed as Independent Non-Executive Chairman for Emyria Ltd
Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) focused on developing innovative treatments for mental health and neurological conditions, is pleased to announce the appointment of Greg Hutchinson as Independent Non-Executive Chairman.
HIGHLIGHTS
Strategic Appointment: Emyria welcomes Mr. Greg Hutchinson as Independent Non-Executive Chairman to bolster the Company's innovative mental health research and development programs
Extensive Healthcare Leadership: Greg Hutchinson's tenure as CEO of Sonic HealthPlus and Deputy CEO of Sonic Clinical Services underscores significant expertise in scaling frontline health services and research programs
New frontier in Psychedelic-Assisted Therapy: Emyria poised to become a global leader in psychedelic-assisted therapy, following Australia's historic legalisation of MDMA and psilocybin for specified mental health conditions 1
Mr. Hutchinson has held leadership roles in rapidly scaling clinical services delivery for over 30 years, spending the last 13 as the CEO of Sonic HealthPlus and Deputy CEO of Sonic Clinical Services, subsidiaries of Sonic Healthcare Limited (ASX: SHL) an S&P/ASX 100 company.
Under Mr. Hutchinson’s tenure, Sonic HealthPlus has become the largest provider of occupational and community medical services in Australia with a workforce of over 1,800 employees and contractors operating across more than 40 metropolitan, regional and remote locations in all States and Territories. At any one time, Sonic HealthPlus attends to some 7,000 active clients, ranging from small entities to some of the world’s foremost corporations across all industry sectors, as well as large government contracts with major Commonwealth and State agencies.
Mr. Hutchinson is also the deputy CEO and a Director of Sonic Healthcare’s clinical services division which encompasses approximately 5,000 employees and 2,500 doctors across some of Australia’s leading healthcare businesses.
Notably, Mr. Hutchinson's professional background also encompasses the founding and scaling of innovative clinical delivery care models and commercial activities.
Mr. Hutchinson co-founded 5D Clinics, a Perth-based radiation oncology business pioneering radiosurgery with CyberKnife technology. The clinic, renowned for its advanced treatment of malignant and benign tumours, has become a key referral centre for Australian and international patients and is expanding across Australia.
Previously, Mr. Hutchinson founded a successful chain of private physiotherapy clinics across Australia which were eventually acquired by Sonic HealthPlus.
Mr. Hutchinson has served as a Board Member of Tennis Australia since 2015.
Dr. Stewart Washer, who has made invaluable contributions to Emyria as Chairman, will be stepping down to an unpaid advisory role where he will continue to provide strategic support for Emyria.
Emyria CEO and MD, Dr. Michael Winlo, praised Dr. Washer's leadership: "Stewart has been instrumental in our journey so far, laying the foundations of a company committed to personalised therapy and data acquisition to guide the development of innovative treatments to address unmet clinical needs.
“We are excited to welcome Greg, whose exceptional track record in founding and scaling clinical operations and healthcare management will be pivotal in our next growth phase, particularly in expanding our MDMA-assisted therapy program."
This transition comes at a crucial time as Emyria embarks on expanding its mental health treatment portfolio and impact. Having already provided care to over 15,000 patients through its clinical services subsidiary, Emerald Clinics, Emyria's recent acquisition of the Pax Centre3, a leading psychological trauma treatment centre, further amplifies its capability for frontline service delivery and evidence-based research. The Company's active clinical trial in MDMA-assisted therapy and the recent arrival of patient-ready drug supply into Australia highlights its preparedness and commitment to developing this novel treatment with an initial focus on patients with Post-Traumatic Stress Disorder (‘PTSD’) - a condition affecting ~ 1,000,000 Australians.2
Click here for the full ASX Release
This article includes content from Emyria Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
Goodness Growth Holdings Announces Third Quarter 2023 Results
Q3 revenue of $24.7 million increased 44.0% YoY and 28.2% sequentially excluding discontinued operations –
– Stronger revenue growth and margins largely driven by adult-use activation in Maryland –
– Record operating income reflects Maryland's performance and early returns on our strategic plan, despite continued headwinds in New York –
– New York divestiture process taking longer than anticipated –
MINNEAPOLIS, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and great value to its customers, today reported financial results for its third quarter ended September 30, 2023. Key financial results are presented below in summary form with supporting commentary and discussion from management of certain key operating metrics which the Company uses to judge its performance. All currency figures referenced herein are denominated in U.S. dollars.
Summary of Key Financial Metrics | Three Months Ended | Nine Months Ended | |||||||||
US $ in millions | September 30, | September 30, | |||||||||
2023 | 2022 | Variance | 2023 | 2022 | Variance | ||||||
GAAP Revenue | $24.7 | $18.9 | 30.9% | $64.0 | $55.6 | 15.1% | |||||
Revenue (excluding discontinued operations) | $24.7 | $17.1 | 44.0% | $62.0 | $48.2 | 28.4% | |||||
GAAP Gross Profit | $13.2 | $9.5 | 38.4% | $32.0 | $22.4 | 43.1% | |||||
Gross Profit Margin | 53.5% | 50.6% | 290 bps | 50.1% | 40.3% | 980 bps | |||||
SG&A Expenses | $6.7 | $8.5 | -20.5% | $22.0 | $26.4 | -16.8% | |||||
SG&A Expenses (% of Sales) | 27.4% | 45.0% | 1,760 bps | 34.3% | 47.5% | 1,320 bps | |||||
Operating Income (Loss) | $5.9 | ($0.2) | NM | $5.2 | ($7.6) | NM | |||||
Operating Income Margin | 23.8% | (1.0%) | 2,480 bps | 8.1% | -13.7% | 2,180 bps | |||||
EBITDA | $7.0 | ($1.2) | NM | $11.3 | ($10.8) | NM | |||||
EBITDA Margin | 28.5% | (6.5%) | 3,500 bps | 17.7% | (19.4%) | 3,710 bps | |||||
NM = Not Meaningful | |||||||||||
Management Commentary
Interim Chief Executive Officer Josh Rosen commented, "The strength of our third quarter results reflects a combination of benefits from our recent operational improvement initiatives and regulatory catalysts in Maryland following the launch of adult use sales in July. We are very proud of our team, who have adapted quickly to our decentralized approach to operations. These efforts and the substantial regulatory catalyst in Maryland enabled us to produce positive cash flow from operations in the quarter. De-risking our balance sheet remains a critical focus, and while we have not yet executed definitive documents related to our divestiture process in New York, we expect to do so before the end of this year and look forward to sharing more visibility into our future profitability expectations once that process is complete."
Amber Shimpa, President and CEO of Vireo Health of Minnesota commented, "Our operational key performance indicators continued to improve during the quarter despite the seasonal challenges we experience in our greenhouse environment in Minnesota. We are encouraged by the strength of our performance in the Maryland market following the implementation of adult-use. Based on early indications, we believe we are outpacing the overall market growth in Maryland, which is an internal goal and standard by which we measure our performance. In Minnesota, we remain focused on driving better value and quality of products for patients as we move out of what is seasonally a very challenging climate for our flower production."
Core Market KPIs 1 | Three Months Ended | Nine Months Ended | |||||||||
US $ in millions | September 30, | September 30, | |||||||||
2023 | 2022 | Variance | 2023 | 2022 | Variance | ||||||
Total Harvest Pounds (Biomass) | 9,111 | 7,530 | 21.0% | 27,142 | 20,727 | 30.9% | |||||
% "A" Flower 2 | 20.5 % | 18.7 % | 180 bps | 19.5 % | 16.9 % | 260 bps | |||||
Total Retail Revenue | $20.1 | $14.7 | 37.4% | $51.8 | $40.9 | 26.8% | |||||
Same Store Sales Growth | - | - | 37.4% | - | - | 26.8% | |||||
Minnesota | - | - | 15.0 % | - | - | 26.6 % | |||||
New York | - | - | -14.0% | - | - | -16.7% | |||||
Maryland | - | - | 229.4 % | - | - | 88.7 % | |||||
Total Wholesale Revenue | $4.5 | $2.5 | 83.7% | $9.9 | $7.4 | 34.5% | |||||
1 Core Markets refer to the Company's operations in Maryland, Minnesota, and New York. | |||||||||||
2 "A Flower" refers to produced biomass that meet the Company's highest internal standards for flower quality, size, and appearance. | |||||||||||
Other Events
On August 14, 2023, the Company announced that it has entered into consulting, licensing and wholesale agreements with two additional dispensaries in Maryland that are owned and controlled by HA-MD LLC and currently operate under the Ethos brand name. The agreements will result in the two Ethos dispensaries in Hampden and Rockville being, upon regulatory approval, rebranded to Green Goods® and include an option to acquire the two dispensaries if and when allowed by applicable law and regulations.
On October 5, 2023, the Company announced that it completed previously disclosed warrant issuances with Grown Rogue International, Inc. Goodness Growth issued 10,000,000 warrants to purchase subordinate voting shares of Goodness Growth to Grown Rogue, with a strike price equal to C$0.317 (US$0.233), which represented a 25.0 percent premium to the 10-day volume weighted average price ("VWAP") of Goodness Growth's subordinate voting shares on the trading day immediately prior to the effective date of the Agreement. Similarly, Grown Rogue issued 8,500,000 warrants to purchase shares of Grown Rogue to Goodness Growth, with a strike price equal to C$0.225 (US$0.166), which represented a 25.0 percent premium to the 10-day VWAP of Grown Rogue's subordinate voting shares on the trading day immediately prior to the effective date of the Agreement. The warrants exchanged in the agreement were issued with five-year terms to exercise.
On October 30, 2023, the Company announced that it executed a fifth amendment to its lease with its landlord on its cannabis cultivation and manufacturing facilities located in Johnstown, New York. The Company and its landlord agreed to increase the tenant improvement allowance on the lease by an additional $14.0 million, with the increase in funds to be utilized to support the completion of the construction of the Company's indoor expansion project which was announced in September 2021. The parties also agreed to a monthly base rental increase of $210,000 beginning November 2023. Goodness Growth management stated that the amendment is intended to support the Company's ongoing divestment process in the State of New York.
Balance Sheet and Liquidity
As of September 30, 2023, total current assets were $135.1 million, including cash on hand of $13.3 million. Total current liabilities were $165.4 million.
As of September 30, 2023, including the required issuance of warrants to Grown Rogue International, Inc., the Company had a total of 143,126,330 equity shares issued and outstanding on an as-converted basis, 236,986,611 shares outstanding on an as-converted, fully diluted basis, and 153,573,359 fully-diluted shares outstanding on the treasury method basis.
Conference Call and Webcast Information
Goodness Growth management will host a conference call with research analysts today, November 14, 2023, at 5:00 p.m. ET (4:00 p.m. CT) to discuss its financial results for its third quarter ended September 30, 2023. Interested parties may attend the conference call by dialing 1-888-414-4585 (Toll-Free) (US and Canada) or 1-646-960-0331 (Toll) (International) and referencing conference ID number 8663261.
A live audio webcast of this event will also be available in the Events & Presentations section of the Company's Investor Relations website and via the following link:
https://events.q4inc.com/attendee/917057239 .
About Goodness Growth Holdings, Inc.
Goodness Growth Holdings, Inc. is a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. Today, the Company is licensed to grow, process, and/or distribute cannabis in four markets and operates 14 dispensaries in three states. For more information about Goodness Growth Holdings, please visit www.goodnessgrowth.com .
Additional Information
Additional information relating to the Company's third quarter 2023 results will be available on EDGAR and SEDAR later today. Goodness Growth refers to certain non-GAAP financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) in circumstances in which the Company believes that doing so provides additional perspective and insights when analyzing the core operating performance of the business. These measures do not have any standardized meaning and may not be comparable to similar measures presented by other issuers. Please see the Supplemental Information and Reconciliation of Non-GAAP Financial Measures at the end of this news release for more detailed information regarding non-GAAP financial measures.
Contact Information
Investor Inquiries: Sam Gibbons Managing Director sam.gibbons@alpha-ir.com (612) 314-8995 | Media Inquiries: Amanda Hutcheson Senior Manager, Communications amandahutcheson@goodnessgrowth.com (919) 815-1476 |
Forward-Looking Statement Disclosure
This press release contains "forward-looking information" within the meaning of applicable United States and Canadian securities legislation. To the extent any forward-looking information in this press release constitutes "financial outlooks" within the meaning of applicable United States or Canadian securities laws, this information is being provided as preliminary financial results; the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such financial outlooks. Forward-looking information contained in this press release may be identified by the use of words such as "should," "believe," "estimate," "would," "looking forward," "may," "continue," "expect," "expected," "will," "likely," "intend," "subject to," "transformation," and "pending," variations of such words and phrases, or any statements or clauses containing verbs in any future tense. These statements should not be read as guarantees of future performance or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company or its subsidiaries to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements or information contained in this press release. Financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to various risks as set out herein and in our Annual Report on Form 10-K filed with the Securities Exchange Commission. Our actual financial position and results of operations may differ materially from management's current expectations and, as a result, our revenue, EBITDA, and cash on hand may differ materially from the values provided in this press release. Forward-looking information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of management's experience and perception of trends, current conditions, and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.
Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, the reader should not place undue reliance on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to: risks related to the timing and content of adult-use legislation in markets where the Company currently operates; current and future market conditions, including the market price of the subordinate voting shares of the Company; risks related to epidemics and pandemics; federal, state, local, and foreign government laws, rules, and regulations, including federal and state laws and regulations in the United States relating to cannabis operations in the United States and any changes to such laws or regulations; operational, regulatory and other risks; execution of business strategy; management of growth; difficulties inherent in forecasting future events; conflicts of interest; risks inherent in an agricultural business; risks inherent in a manufacturing business; liquidity and the ability of the Company to raise additional financing to continue as a going concern; the Company's ability to meet the demand for flower in Minnesota; risk of failure in the lawsuit with Verano and the cost of that litigation; our ability to dispose of our assets held for sale at an acceptable price or at all; and risk factors set out in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, which is available on EDGAR with the U.S. Securities and Exchange Commission and filed with the Canadian securities regulators and available under the Company's profile on SEDAR at www.sedar.com .
The statements in this press release are made as of the date of this release. Except as required by law, we undertake no obligation to update any forward-looking statements or forward-looking information to reflect events or circumstances after the date of such statements.
Supplemental Information
The financial information reported in this news release is based on unaudited financial statements for the fiscal quarters ended September 30, 2023, and September 30, 2022. All financial information contained in this news release is qualified in its entirety with reference to such financial statements. To the extent that the financial information contained in this news release is inconsistent with the information contained in the Company's audited financial statements, the financial information contained in this news release shall be deemed to be modified or superseded by the Company's audited financial statements. The making of a modifying or superseding statement shall not be deemed an admission for any purposes that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws.
GOODNESS GROWTH HOLDINGS, INC. | ||||||||
CONSOLIDATED BALANCE SHEETS AS OF 9/30/2023 AND 12/31/2022 | ||||||||
(Amounts Expressed in United States Dollars, Unaudited and Condensed) | ||||||||
September 30, | December 31, | |||||||
2023 | 2022 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash | $ | 13,296,137 | $ | 15,149,333 | ||||
Accounts receivable, net of allowance for doubtful accounts of $344,937 and $453,860, respectively | 5,688,782 | 4,286,072 | ||||||
Inventory | 19,056,338 | 20,508,023 | ||||||
Prepayments and other current assets | 1,834,013 | 2,544,532 | ||||||
Notes receivable, current | 3,750,000 | — | ||||||
Warrants Receivable | 1,566,445 | — | ||||||
Assets Held for Sale | 89,918,392 | 4,240,781 | ||||||
Total current assets | 135,110,107 | 46,728,741 | ||||||
Property and equipment, net | 23,812,949 | 89,606,932 | ||||||
Operating lease, right-of-use asset | 2,182,174 | 6,110,787 | ||||||
Notes receivable, long-term | — | 3,750,000 | ||||||
Intangible assets, net | 8,935,019 | 8,776,946 | ||||||
Goodwill | — | 183,836 | ||||||
Deposits | 383,645 | 2,312,161 | ||||||
Deferred tax assets | 1,245,000 | 1,687,000 | ||||||
Total assets | $ | 171,668,894 | $ | 159,156,403 | ||||
Liabilities | ||||||||
Current liabilities | ||||||||
Accounts Payable and Accrued liabilities | $ | 33,638,534 | $ | 14,928,780 | ||||
Long-Term debt, current portion | 55,432,463 | 11,780,000 | ||||||
Right of use liability | 907,998 | 1,680,294 | ||||||
Liabilities held for sale | 75,439,119 | 1,319,847 | ||||||
Total current liabilities | 165,418,114 | 29,708,921 | ||||||
Right-of-use liability | 9,700,492 | 79,757,994 | ||||||
Other long-term liabilities | 235,577 | — | ||||||
Convertible debt, net | 5,107,477 | — | ||||||
Long-Term debt | 4,060,633 | 46,248,604 | ||||||
Total liabilities | $ | 184,522,293 | $ | 155,715,519 | ||||
Stockholders' equity | ||||||||
Subordinate Voting Shares ($- par value, unlimited shares authorized; 108,332,330 shares issued and outstanding) | — | — | ||||||
Multiple Voting Shares ($- par value, unlimited shares authorized; 347,940 shares issued and outstanding) | — | — | ||||||
Super Voting Shares ($- par value; unlimited shares authorized; 0 shares issued and outstanding) | — | — | ||||||
Additional Paid in Capital | 185,991,816 | 181,321,847 | ||||||
Accumulated deficit | (198,845,215 | ) | (177,880,963 | ) | ||||
Total stockholders' equity | $ | (12,853,399 | ) | $ | 3,440,884 | |||
Total liabilities and stockholders' equity | $ | 171,668,894 | $ | 159,156,403 | ||||
GOODNESS GROWTH HOLDINGS, INC. | ||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 | ||||||||||||||||
(Amounts Expressed in United States Dollars, Unaudited and Condensed) | ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Revenue | $ | 24,675,145 | $ | 18,854,101 | $ | 63,960,125 | $ | 55,582,821 | ||||||||
Cost of sales | ||||||||||||||||
Product costs | 10,493,561 | 9,186,241 | 30,347,357 | 29,532,469 | ||||||||||||
Inventory valuation adjustments | 984,196 | 131,000 | 1,563,872 | 3,657,788 | ||||||||||||
Gross profit | 13,197,388 | 9,536,860 | 32,048,896 | 22,392,564 | ||||||||||||
Operating expenses: | ||||||||||||||||
Selling, general and administrative | 6,749,314 | 8,489,728 | 21,965,576 | 26,393,136 | ||||||||||||
Stock-based compensation expenses | 296,617 | 896,081 | 4,009,415 | 2,636,594 | ||||||||||||
Depreciation | 99,929 | 167,940 | 377,121 | 487,164 | ||||||||||||
Amortization | 180,034 | 172,267 | 498,828 | 516,800 | ||||||||||||
Total operating expenses | 7,325,894 | 9,726,016 | 26,850,940 | 30,033,694 | ||||||||||||
Gain (loss) from operations | 5,871,494 | (189,156 | ) | 5,197,956 | (7,641,130 | ) | ||||||||||
Other income (expense): | ||||||||||||||||
Impairment of long-lived assets | — | (2,108,703 | ) | — | (7,476,618 | ) | ||||||||||
Gain (loss) on disposal of assets | (50,686 | ) | — | (2,798,567 | ) | 168,359 | ||||||||||
Gain (loss) on sale of property and equipment | — | 7,583 | — | (3,347 | ) | |||||||||||
Interest expenses, net | (7,915,658 | ) | (5,573,263 | ) | (22,795,242 | ) | (15,472,885 | ) | ||||||||
Other income (expenses) | 345,824 | 79,750 | 6,166,472 | 1,196,975 | ||||||||||||
Other income (expenses), net | (7,620,520 | ) | (7,594,633 | ) | (19,427,337 | ) | (21,587,516 | ) | ||||||||
Loss before income taxes | (1,749,026 | ) | (7,783,789 | ) | (14,229,381 | ) | (29,228,646 | ) | ||||||||
Current income tax expenses | (3,980,000 | ) | (1,790,000 | ) | (7,357,871 | ) | (4,130,000 | ) | ||||||||
Deferred income tax recoveries | 500,000 | 1,150,000 | 623,000 | 4,185,000 | ||||||||||||
Net loss and comprehensive loss | (5,229,026 | ) | (8,423,789 | ) | (20,964,252 | ) | (29,173,646 | ) | ||||||||
Net loss per share - basic and diluted | $ | (0.04 | ) | $ | (0.07 | ) | $ | (0.16 | ) | $ | (0.23 | ) | ||||
Weighted average shares used in computation of net loss per share - basic & diluted | 141,332,852 | 128,120,949 | 132,576,879 | 128,114,570 | ||||||||||||
GOODNESS GROWTH HOLDINGS, INC. | ||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 | ||||||||
(Amounts Expressed in United States Dollars, Unaudited and Condensed) | ||||||||
September 30, | ||||||||
2023 | 2022 | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
Net loss | $ | (20,964,252 | ) | $ | (29,173,646 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Inventory valuation adjustments | 1,563,872 | 3,657,788 | ||||||
Depreciation | 377,121 | 487,164 | ||||||
Depreciation capitalized into inventory | 1,846,418 | 1,959,536 | ||||||
Non-cash operating lease expense | 423,821 | 852,687 | ||||||
Amortization of intangible assets | 498,828 | 516,800 | ||||||
Amortization of intangible assets capitalized into inventory | 24,779 | — | ||||||
Stock-based payments | 4,009,415 | 2,636,594 | ||||||
Warrants receivable | (1,566,445 | ) | — | |||||
Interest Expense | 5,111,930 | 3,430,733 | ||||||
Impairment of long-lived assets | — | 7,476,618 | ||||||
Deferred income tax | (623,000 | ) | (4,185,000 | ) | ||||
Accretion | 800,392 | 3,407,030 | ||||||
Loss (gain) on sale of property and equipment | — | 3,347 | ||||||
Loss on disposal of Red Barn Growers | 2,909,757 | — | ||||||
Loss (gain) on disposal of assets | (111,190 | ) | — | |||||
Gain on disposal of royalty asset | — | (168,359 | ) | |||||
Change in operating assets and liabilities: | ||||||||
Accounts Receivable | (902,709 | ) | (1,408,580 | ) | ||||
Prepaid expenses | 684,987 | (1,601,742 | ) | |||||
Inventory | (1,932,554 | ) | (2,205,236 | ) | ||||
Accounts payable and accrued liabilities | 7,459,350 | 2,360,044 | ||||||
Change in assets and liabilities held for sale | (116,882 | ) | — | |||||
Net cash used in operating activities | $ | (506,362 | ) | $ | (11,954,222 | ) | ||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
PP&E Additions | $ | (2,630,724 | ) | $ | (4,938,587 | ) | ||
Intangible license additions | (1,090,919 | ) | — | |||||
Proceeds from sale of Red Barn Growers net of cash | 439,186 | 387,512 | ||||||
Proceeds from sale of property, plant, and equipment | 242,088 | — | ||||||
Proceeds from sale of royalty asset | — | 236,635 | ||||||
Deposits | (263,545 | ) | (482,539 | ) | ||||
Net cash provided by (used in) investing activities | $ | (3,303,914 | ) | $ | (4,796,979 | ) | ||
CASH FLOWS FROM FINANCING ACTIVITIES | $ | $ | ||||||
Proceeds from long-term debt, net of issuance costs | — | 24,868,143 | ||||||
Proceeds from convertible debt, net of issuance costs | 5,348,140 | — | ||||||
Proceeds from option exercises | — | 7,201 | ||||||
Debt principal payments | (1,976,362 | ) | — | |||||
Lease principal payments | (1,414,698 | ) | (1,437,346 | ) | ||||
Net cash provided by (used in) financing activities | $ | 1,957,080 | $ | 23,437,998 | ||||
Net change in cash | $ | (1,853,196 | ) | $ | 6,686,797 | |||
Cash, beginning of period | $ | 15,149,333 | $ | 15,155,279 | ||||
Cash, end of period | $ | 13,296,137 | $ | 21,842,076 | ||||
GOODNESS GROWTH HOLDINGS, INC. STATE-BY-STATE REVENUE PERFORMANCE THREE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 | ||||||||||||||||
Three Months Ended | ||||||||||||||||
September 30, | ||||||||||||||||
2023 | 2022 | $ Change | % Change | |||||||||||||
Retail: | ||||||||||||||||
MN | $ | 11,791,001 | $ | 10,252,523 | $ | 1,538,478 | 15 | % | ||||||||
NY | 2,185,701 | 2,541,913 | (356,212 | ) | (14 | ) | % | |||||||||
NM | — | 1,721,017 | (1,721,017 | ) | (100 | ) | % | |||||||||
MD | 6,170,372 | 1,873,773 | 4,296,599 | 229 | % | |||||||||||
Total Retail | $ | 20,147,074 | $ | 16,389,226 | $ | 3,757,848 | 23 | % | ||||||||
Wholesale: | ||||||||||||||||
MD | 2,923,376 | 1,333,864 | 1,589,512 | 119 | % | |||||||||||
NY | 1,375,730 | 1,131,011 | 244,719 | 22 | % | |||||||||||
NM | — | — | — | 100 | % | |||||||||||
Total Wholesale | $ | 4,299,106 | $ | 2,464,875 | $ | 1,834,231 | 74 | % | ||||||||
MD Service Revenue | 228,965 | — | 228,965 | 100 | % | |||||||||||
Total Revenue | $ | 24,675,145 | $ | 18,854,101 | $ | 5,821,044 | 31 | % | ||||||||
AZ and NM Revenue | $ | — | $ | (1,721,017 | ) | $ | 1,721,017 | (100 | ) | % | ||||||
Total Revenue excluding AZ and NM | $ | 24,675,145 | $ | 17,133,084 | $ | 7,542,061 | 44 | % | ||||||||
GOODNESS GROWTH HOLDINGS, INC. STATE-BY-STATE REVENUE PERFORMANCE NINE MONTHS ENDED SEPTEMBER 30, 2023 AND 2022 | ||||||||||||||||
Nine Months Ended | ||||||||||||||||
September 30, | ||||||||||||||||
2023 | 2022 | $ Change | % Change | |||||||||||||
Retail: | ||||||||||||||||
MN | $ | 33,989,289 | $ | 26,844,812 | $ | 7,144,477 | 27 | % | ||||||||
NY | 6,827,278 | 8,193,540 | (1,366,262 | ) | (17 | ) | % | |||||||||
NM | 1,964,285 | 4,984,945 | (3,020,660 | ) | (61 | ) | % | |||||||||
MD | 10,981,121 | 5,819,644 | 5,161,477 | 89 | % | |||||||||||
Total Retail | $ | 53,761,973 | $ | 45,842,941 | $ | 7,919,032 | 17 | % | ||||||||
Wholesale: | ||||||||||||||||
AZ | $ | — | $ | 2,355,683 | $ | (2,355,683 | ) | (100 | ) | % | ||||||
MD | 6,324,396 | 4,162,287 | 2,162,109 | 52 | % | |||||||||||
NY | 3,605,064 | 2,549,770 | 1,055,294 | 41 | % | |||||||||||
NM | 39,727 | — | 39,727 | 100 | % | |||||||||||
MN | — | 672,140 | (672,140 | ) | (100 | ) | % | |||||||||
Total Wholesale | $ | 9,969,187 | $ | 9,739,880 | $ | 229,307 | 2 | % | ||||||||
MD Service Revenue | 228,965 | - | 228,965 | 100 | % | |||||||||||
Total Revenue | $ | 63,960,125 | $ | 55,582,821 | $ | 8,377,304 | 15 | % | ||||||||
AZ and NM Revenue | $ | (2,004,012 | ) | $ | (7,340,628 | ) | $ | 5,336,616 | (73 | ) | % | |||||
Total Revenue excluding AZ and NM | $ | 61,956,113 | $ | 48,242,193 | $ | 13,713,920 | 28 | % | ||||||||
Reconciliation of Non-GAAP Financial Measures
Goodness Growth management occasionally elects to provide certain non-GAAP financial measures such as Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA). EBITDA is a non-GAAP measure and does not have a standardized definition under GAAP. The following information provides reconciliations of the supplemental non-GAAP financial measures, presented herein to the most directly comparable financial measures calculated and presented in accordance with GAAP. The Company has provided the non-GAAP financial measures, which are not calculated or presented in accordance with GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with GAAP. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented.
Reconciliation of Net Loss to EBITDA | ||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
September 30, | September 30, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Net income (loss) | $ | (5,229,026 | ) | $ | (8,423,789 | ) | (20,964,252 | ) | (29,173,646 | ) | ||||||
Interest expense, net | 7,915,658 | 5,573,263 | 22,795,242 | 15,472,885 | ||||||||||||
Income taxes | 3,480,000 | 640,000 | 6,734,871 | (55,000 | ) | |||||||||||
Depreciation & Amortization | 279,963 | 340,207 | 875,949 | 1,003,964 | ||||||||||||
Depreciation included in cost of goods sold | 577,132 | 645,480 | 1,871,197 | 1,959,536 | ||||||||||||
EBITDA (non-GAAP) | $ | 7,023,727 | $ | (1,224,839 | ) | 11,313,007 | (10,792,261 | ) | ||||||||
News Provided by GlobeNewswire via QuoteMedia
Melodiol Global Health Investor Kit
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
Latest Press Releases
Related News
TOP STOCKS
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.